T3	eligibility 439 511	Patients who had received no more than one previous chemotherapy regimen
T4	intervention 91 115	cetuximab with cisplatin
T5	control 123 138	cisplatin alone
T6	intervention-participants 1045 1048	115
T7	control-participants 1097 1099	58
T9	iv-bin-percent 1237 1240	20%
T10	cv-bin-percent 1294 1297	10%
T13	outcome 1432 1435	PFS
T14	iv-cont-median 1475 1478	3.7
T15	cv-cont-median 1481 1491	1.5 months
T18	outcome 1565 1574	median OS
T19	iv-cont-median 1579 1583	12.9
T20	cv-cont-median 1591 1601	9.4 months
T23	outcome 1686 1726	acne-like rash, neutropenia, and fatigue
T1	outcome 1229 1232	ORR
T8	outcome 1652 1676	grade 3/4 adverse events
T2	outcome-Measure 781 808	overall response rate (ORR)
T11	outcome-Measure 848 879	progression-free survival (PFS)
T12	outcome-Measure 881 902	overall survival (OS)
T16	outcome-Measure 908 923	safety profiles
